The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-a) inhibitors by entities that manufacture TNF alpha inhibitors. TNF alpha inhibitors are a group of medicines that conquer the body’s natural response to TNF, a protein produced by white blood cells, involved in early inflammatory events. These are important treatments in the number of inflammatory conditions including spondylarthritis, psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).
The global TNF alpha inhibitors market is expected to decline from $40.66 billion in 2019 to $39.01 billion in 2020 at a compound annual growth rate (CAGR) of -4.06%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $42.86 billion in 2023 at a CAGR of 3.18%.
